[1]
Wełnicki, M. 2025. Why we choose fenofibrate? Fenofibrate in long-term therapy – larger packages, greater benefits for patients with atherogenic dyslipidemia. Medycyna Faktow (J EBM). 18, 2(67) (Jun. 2025), 290-292. DOI:https://doi.org/10.24292/01.MF.0225.18.